Core Viewpoint - A class action securities lawsuit has been filed against Perrigo Company plc, alleging securities fraud that affected investors between February 27, 2023, and November 4, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Perrigo's acquisition of the infant formula business from Nestlé was significantly underinvested in maintenance and operational improvements [2]. - It is alleged that Perrigo needed to incur substantial capital and operational expenditures beyond previously stated cost estimates to address issues in the infant formula business [2]. - The complaint points out significant manufacturing deficiencies in the facility dedicated to the infant formula business [2]. - As a result of these issues, Perrigo's financial results, including earnings and cash flow, were reportedly overstated [2]. - The positive statements made by the defendants regarding the Company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Stride, Inc. ("Stride" or the "Company") (NYSE: LRN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Stride investors who were adversely affected by alleged securities fraud between October 22, 2024 and October 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/stride-inc-lawsuit-submission-form ...

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud related to the company's product, Novum LVP, which reportedly has systemic defects leading to serious patient risks [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Baxter's Novum LVP product has systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [2]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths linked to these defects but failed to implement adequate remedial measures [2]. - The complaint suggests that Baxter's statements regarding the safety, efficacy, and sales prospects of the Novum LVP were materially false and misleading [2]. Group 2: Investor Information - Investors who suffered losses during the specified period (February 23, 2022, to July 30, 2025) have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing significant recoveries for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Freeport-McMoRan Inc. ("Freeport-McMoRan Inc." or the "Company") (NYSE: FCX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Freeport-McMoRan Inc. investors who were adversely affected by alleged securities fraud between February 15, 2022 and September 24, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/ ...

Core Viewpoint - A class action securities lawsuit has been filed against WPP plc, alleging securities fraud that negatively impacted investors between February 27, 2025, and July 8, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that WPP provided overly positive statements while concealing material adverse facts about its media arm's ability to handle macroeconomic challenges and competition, leading to a loss of market share [2]. - On July 9, 2025, WPP reported a deterioration in performance for Q2 2025, attributing this to macroeconomic uncertainty and weaker new business, compounded by distractions from ongoing restructuring [2]. - Following the trading update, WPP's stock price fell from $35.82 to $29.34 per share, marking an approximate decline of 18.1% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until December 8, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4].

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Inspire Medical Systems, Inc. ("Inspire Medical Systems, Inc." or the "Company") (NYSE: INSP) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Inspire Medical Systems, Inc. investors who were adversely affected by alleged securities fraud between August 6, 2024 and August 4, 2025. Follow the link below to get more information and be contacted by a member of our team ...

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Molina Healthcare, Inc. ("Molina" or the "Company") (NYSE: MOH) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Molina investors who were adversely affected by alleged securities fraud between February 5, 2025 and July 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/molina-healthcare-inc-laws ...

Core Viewpoint - A class action securities lawsuit has been filed against CarMax, Inc. alleging securities fraud that affected investors between June 20, 2025, and November 5, 2025 [1][2] Group 1: Allegations - The lawsuit claims that defendants made false statements regarding CarMax's growth prospects, suggesting that earlier growth was a temporary benefit due to customer speculation about tariffs [2] - It is alleged that the statements made by defendants about CarMax's business operations and prospects were materially false and misleading, lacking a reasonable basis [2] Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until January 2, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Law Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

FCX SHAREHOLDERS: Freeport-McMoRan Inc. Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by January 12December 01, 2025 3:18 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - December 1, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Freeport-McMoRan Inc. (NYSE: FCX) and certain of the Company's senior executives for securities fraud after significan ...

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. for securities fraud, following a significant drop in stock price attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of California, titled Kim v. Synopsys, Inc., et al., No. 3:25-cv-09410 [3]. - Investors have until December 30, 2025, to request to be appointed to lead the case [3]. Group 2: Company Performance - Synopsys provides design automation software products, with its Design IP segment being the fastest-growing, increasing from 25% of revenue in 2022 to 31% in 2024 [4]. - The company reported Q3 2025 results showing a revenue decline in the Design IP segment to $425.9 million, a 7.7% decrease year-over-year, and a net income of $242.5 million, down 43% year-over-year [6]. Group 3: Market Reaction - Following the Q3 2025 results announcement, Synopsys stock fell nearly 36%, from $604.37 per share to $387.78 per share [6]. - The decline was attributed to revelations that Design IP customers required more customization, impacting the business model and economics of the segment [5][6].